MktsMarkets

Arbutus Biopharma Corporation
NASDAQ: ABUSKey statistics
ABUS News
Stories mentioning ABUS from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 179,126 | 1,051 | 529.00 | 10,739 | 1,764 | 1,574 | 1,339 | 1,726 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 4,120 | 5,006 | 5,778 | 5,498 | 8,959 | 8,810 | 14,273 | 15,551 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 10,218 | 6,341 | 9,188 | 9,251 | 27,463 | 15,507 | 22,779 | 23,309 |
| Operating Income (Loss) | 168,908 | (5,290) | (8,659) | 1,488 | (25,699) | (13,933) | (21,440) | (21,583) |
| Interest Income | 815.00 | 877.00 | 952.00 | 1,042 | 1,197 | 1,464 | 1,747 | 1,829 |
| Interest Expense | 34.00 | |||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | 0.00 | |||||||
| Net Income (Loss) | 169,695 | (3,756) | (7,742) | 2,523 | (24,526) | (12,532) | (19,717) | (19,796) |
| Earnings Per Share (Basic) | 0.88 | (0.02) | (0.04) | 0.01 | (0.13) | (0.07) | (0.10) | (0.11) |
| Earnings Per Share (Diluted) | 0.87 | (0.02) | (0.04) | 0.01 | (0.13) | (0.07) | (0.10) | (0.11) |
| Weighted Average Shares Outstanding (Basic) | 193,769 | 191,600 | 191,779 | 191,551 | 190,707 | 185,609 | 188,997 | 188,041 |
| Weighted Average Shares Outstanding (Diluted) | 195,214 | 191,600 | 191,779 | 192,400 | 190,707 | 185,609 | 188,997 | 188,041 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ABUS
Arbutus Biopharma Corporation (NASDAQ: ABUS) is a stock listed on the Nasdaq Stock Market under the ticker symbol ABUS. It last traded at $4.02 (Nov 20, 2026, 4:00 PM ET), down 1.2% on the day. That gives Arbutus Biopharma a market capitalisation of $617.0M and a price-to-earnings ratio of 4.0.
Over the past 52 weeks ABUS has traded between $3.50 and $5.45.
Revenue for the quarter ended Mar 31, 2026 was $179.1M; net income $169.7M. Revenue was up 10055% from $1.8M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $179.1M | $169.7M | 94.7% |
| Dec 31, 2025 | $1.1M | -$3.8M | -357.4% |
| Sep 30, 2025 | $529.0K | -$7.7M | -1463.5% |
| Jun 30, 2025 | $10.7M | $2.5M | 23.5% |
From Arbutus Biopharma’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…